All In Biotech

Drug Trial Radar · NCT06051409

A Study of Olverembatinib in Patients With Newly Diagnosed Ph+ ALL (POLARIS-1)

A Pivotal Registrational Phase 3 Study of Olverembatinib Combined With Chemotherapy Versus Investigator's Choice of TKI Combined With Chemotherapy in Patients With Newly Diagnosed Ph+ ALL

Last checked: Nov 20, 2026Latest source record: Apr 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Title says "pivotal". Randomized with 350 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

350

Planned (sponsor's estimate)

Start

Aug 31, 2023

Primary completion

Dec 31, 2027

Study completion Jun 30, 2029

Sponsor

Lead sponsor
Ascentage Pharma Group Inc.Industry
Sponsor type
Industry
Collaborators
Guangzhou Healthquest Pharma Co., Ltd
First posted
Sep 22, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A global multicenter, open-label, randomized and registrational Phase 3 study to evaluate efficacy and safety of olverembatinib combined with chemotherapy versus investigator's choice of tyrosine kinase inhibitor (TKI) combined with chemotherapy in subjects with newly-diagnosed Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia (Ph+ ALL).

Conditions

  • Ph+ ALL
  • Leukemia, Lymphoblastic, Acute, Philadelphia-Positive

Interventions

  • OlverembatinibDrug

    Oral (PO) once every other day (QOD).

  • Investigator's choice of TKIDrug

    Oral (PO) once daily (QD).

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Minimal Residual Disease Negative CR RateTime frame: Cycle 1 to Cycle 3 (each cycle is 28 days)

Locations

90 sites in 12 countries. Site status is shown where the registry gives one.

  • Ascentage Investigative Site #1044

    Birmingham, Alabama · Not yet recruiting

  • Ascentage Investigative Site #1062

    Duarte, California · Not yet recruiting

  • Ascentage Investigative Site #1134

    Los Angeles, California · Not yet recruiting

  • Ascentage Investigative Site #1059

    Los Angeles, California · Not yet recruiting

  • Ascentage Investigative Site #1142

    Miami, Florida · Not yet recruiting

  • Ascentage Investigative Site #1045

    Augusta, Georgia · Not yet recruiting

  • Ascentage Investigative Site #1158

    Indianapolis, Indiana · Not yet recruiting

  • Ascentage Investigative Site #1069

    Indianapolis, Indiana · Not yet recruiting

  • Ascentage Investigative Site #1084

    Lexington, Kentucky · Not yet recruiting

  • Ascentage Investigative Site #1064

    Hackensack, New Jersey · Not yet recruiting

  • Ascentage Investigative Site #1098

    New Brunswick, New Jersey · Not yet recruiting

  • Ascentage Investigative Site #1160

    Stony Brook, New York · Not yet recruiting

  • Ascentage Investigative Site #1151

    The Bronx, New York · Not yet recruiting

  • Ascentage Investigative Site #1501

    Houston, Texas · Not yet recruiting

  • Ascentage Investigative Site #1806

    Seattle, Washington · Not yet recruiting

  • Ascentage Investigative Site #1155

    Morgantown, West Virginia · Not yet recruiting

  • Royal North Shore Hospital

    St Leonards, New South Wales, Australia · Active not recruiting

  • Royal Adelaide Hospital

    Adelaide, South Australia, Australia · Active not recruiting

  • Alfred Health

    Melbourne, Victoria, Australia · Active not recruiting

  • Royal Perth Hospital

    Perth, Washington, Australia · Active not recruiting

  • The First Affiliated Hospital of Bengbu Medical School

    Bengbu, Anhui, China · Not yet recruiting

  • Xinqiao Hospital of Army Medical University

    Chongqing, Chongqing Municipality, China · Recruiting

  • Guangdong Province People's Hospital

    Guangdong, Guangzhou, China · Recruiting

  • Nanfang Hospital of Southern Medical University

    Guangdong, Guangzhou, China · Recruiting

  • Henan Cancer Hospital

    Zhengzhou, Henan, China · Recruiting

  • Wuhan Union Hospital of Tongji Medical College of Huazhong University of Science and Technology

    Wuhan, Hubei, China · Recruiting

  • The First Affiliated Hospital of Suzhou University

    Suzhou, Jiangsu, China · Recruiting

  • Shanghai Jiao Tong University School of Medicine Ruijin Hospital

    Shanghai, Shanghai Municipality, China · Not yet recruiting

  • West China Hospital of Sichuan University

    Chengdu, Sichuan, China · Recruiting

  • Institute of Blood Transfusion of Chinese Academy of Medical Sciences

    Tianjin, Tianjin Municipality, China · Recruiting

  • Ascentage Investigative Site #8647

    Brno, Czechia · Not yet recruiting

  • Ascentage Investigative Site #6305

    Hradec Králové, Czechia · Not yet recruiting

  • Ascentage Investigative Site #6304

    Ostrava, Czechia · Not yet recruiting

  • Ascentage Investigative Site #6302

    Prague, Czechia · Not yet recruiting

  • Ascentage Investigative Site #6309

    Prague, Czechia · Not yet recruiting

  • Ascentage Investigative Site #5020

    Le Chesnay, France · Not yet recruiting

  • Ascentage Investigative Site #5021

    Lyon, France · Not yet recruiting

  • Ascentage Investigative Site #5013

    Nantes, France · Not yet recruiting

  • Ascentage Investigative Site #5025

    Nice, France · Not yet recruiting

  • Ascentage Investigative Site #5019

    Pessac, France · Not yet recruiting

Showing 40 of 90 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.